Jazz Pharmaceuticals plc
Investing.com, citing Macquarie data for the week ended Aug. 14, reports global biotech funding up 75% year over year. IPOs rose 224% and follow-ons 140%, while private investment in public equity rose 29% and venture funding 38%. Examples include Jazz Pharmaceuticals’ $820M upfront deal for Actio Bio and Silence Therapeutics’ $200M upsized IPO.
Jazz Pharmaceuticals agreed to acquire private Actio Biosciences in a deal potentially worth just over $1.3B. Actio would get $820M upfront and up to $500M tied to regulatory and sales milestones. Actio’s lead KCNT1-related epilepsy drug is in testing. Closing is expected in Q4, with a funded spinout. Jazz reported $1.2B total quarterly revenue, up 16% YoY.
Jazz Pharmaceuticals said it will acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent payments tied to sales or approval milestones. The deal targets Actio’s oral therapy ABS-1230 for KCNT1-related epilepsy, where no FDA-approved treatments exist. Jazz expects closing by Q4, with Actio’s other pipeline spun off into a new private company.
Over the past 7 days, alphai's AI scored 6 news stories mentioning JAZZ (Jazz Pharmaceuticals plc). Coverage has skewed bullish: 5 bullish, 1 neutral, and 0 bearish.
Recent JAZZ coverage spans mergers & acquisitions, regulation and corporate actions.
In the last 30 days, JAZZ insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.5M). The most active reporter was COZADD BRUCE C with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Deal terms and pipeline assets create a near-term M&A catalyst and potential valuation read-through for Jazz.
The announced acquisition is a direct, time-sensitive catalyst for Jazz, expanding its neuroscience and rare epilepsy pipeline.
Deal terms and rare-epilepsy pipeline expansion create a near-term valuation and execution catalyst for JAZZ, with Q4 closing as the key timeline.
Deal announcement is a direct capital allocation and pipeline expansion catalyst for JAZZ, with execution and financing details in focus.
The filing signals a corporate transaction that can change deal risk, timing, and valuation for JAZZ shareholders, pending deal terms and approvals.
alphai scores every news story that mentions JAZZ with an AI model for sentiment and relevance, and aggregates insider trades from Jazz Pharmaceuticals plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Investing.com, citing Macquarie data for the week ended Aug. 14, reports global biotech funding up 75% year over year. IPOs rose 224% and follow-ons 140%, while private investment in public equity rose 29% and venture funding 38%. Examples include Jazz Pharmaceuticals’ $820M upfront deal for Actio Bio and Silence Therapeutics’ $200M upsized IPO.
6 min readJazz Pharmaceuticals agreed to acquire private Actio Biosciences in a deal potentially worth just over $1.3B. Actio would get $820M upfront and up to $500M tied to regulatory and sales milestones. Actio’s lead KCNT1-related epilepsy drug is in testing. Closing is expected in Q4, with a funded spinout. Jazz reported $1.2B total quarterly revenue, up 16% YoY.
4 min readJazz Pharmaceuticals said it will acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent payments tied to sales or approval milestones. The deal targets Actio’s oral therapy ABS-1230 for KCNT1-related epilepsy, where no FDA-approved treatments exist. Jazz expects closing by Q4, with Actio’s other pipeline spun off into a new private company.
3 min readJazz Pharmaceuticals agreed to acquire Actio Biosciences for $820m upfront, plus up to $500m in contingent payments. The deal, approved by both boards, is expected to close in Q4 2026. Jazz will fund it with cash and existing facilities. Actio’s lead asset ABS-1230 targets KCNT1+ epilepsy and is in a Phase Ib/IIa KYRON trial.
4 min readJazz Pharmaceuticals plc (JAZZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 d151973dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 Certain confidential information contained in this exhibit has been omitted by means of redacting a portion of the text and replacing it with [***], pursuant to Regulation S-K Item 601(b) of the Securities Act of 1933, as amende
6 min readJazz Pharmaceuticals (JAZZ) agreed to buy privately held Actio Biosciences for $820M upfront plus up to $500M contingent consideration. Actio’s lead asset ABS-1230 targets KCNT1+ epilepsy, with no FDA-approved therapies. ABS-1230 has Fast Track, Orphan, and Rare Pediatric Disease designations and is in the Phase 1b/2a KYRON trial. JAZZ stock closed at $256.56.
4 min readJazz Pharmaceuticals said it will seek FDA removal of the second-line indication for lurbinectedin (Zepzelca) in metastatic small-cell lung cancer. Jazz plans a labeling supplement submission in Q3 2026. The indication was accelerated in 2020. The phase 3 LAGOON trial failed its overall survival endpoint, with median OS 8.7 vs 10.7 months (HR 1.19) for monotherapy. First-line maintenance remains unchanged.
3 min readCOZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $252.98 ($1.52M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readRegulatory Recon roundup: Eli Lilly plans broader special-access applications for its unapproved obesity drug, while Jazz will withdraw FDA approval for Zepzelca’s second-line small cell lung cancer indication. Other items include Merck’s anti-TL1A mixed trial results, Medicare changes to device payment pathways, and Pfizer earnings and cost-cut targets.
6 min readJazz Pharmaceuticals reported Q2 EPS of $5.71, below the $6.18 consensus, but sales of $1.208B, above the $1.115B estimate. The company increased FY2026 sales guidance to $4.60B-$4.75B from $4.25B-$4.50B. Analysts at Baird, Barclays, and Needham raised price targets after the results; JAZZ shares were up 1.4% premarket to $255.
2 min read
